-transparent.png){kind=logo}
Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: a Southwest Oncology Group study. 1990
S A Taylor, and
T Fleming, and
D D Von Hoff, and
J D McCracken, and
R M Bukowski, and
R W Talley, and
R B Natale, and
J T Guy, and
W E Samlowski, and
J H Costanzi
University of Kansas Medical Center.
Patient with advanced adenocarcinoma of the pancreas and no prior chemotherapy were treated on a Phase II trial of mitoxantrone. Doses were adjusted for hepatic dysfunction as defined by bilirubin. Twenty-four patients with a bilirubin less than or equal to 1.5 mg% received mitoxantrone 12 mg/m2 i.v. repeated every three weeks. Myelosuppression in the form of leukopenia was the major toxicity. There were no responses in twenty-four evaluable patients.
Related Publications
S A Taylor, and
T Fleming, and
D D Von Hoff, and
J D McCracken, and
R M Bukowski, and
R W Talley, and
R B Natale, and
J T Guy, and
W E Samlowski, and
J H Costanzi
February 1985,
Cancer treatment reports,
S A Taylor, and
T Fleming, and
D D Von Hoff, and
J D McCracken, and
R M Bukowski, and
R W Talley, and
R B Natale, and
J T Guy, and
W E Samlowski, and
J H Costanzi
December 1987,
Cancer treatment reports,
S A Taylor, and
T Fleming, and
D D Von Hoff, and
J D McCracken, and
R M Bukowski, and
R W Talley, and
R B Natale, and
J T Guy, and
W E Samlowski, and
J H Costanzi
December 1990,
Journal of biological response modifiers,
S A Taylor, and
T Fleming, and
D D Von Hoff, and
J D McCracken, and
R M Bukowski, and
R W Talley, and
R B Natale, and
J T Guy, and
W E Samlowski, and
J H Costanzi
June 1984,
Cancer treatment reports,
S A Taylor, and
T Fleming, and
D D Von Hoff, and
J D McCracken, and
R M Bukowski, and
R W Talley, and
R B Natale, and
J T Guy, and
W E Samlowski, and
J H Costanzi
July 2001,
Urologic oncology,
S A Taylor, and
T Fleming, and
D D Von Hoff, and
J D McCracken, and
R M Bukowski, and
R W Talley, and
R B Natale, and
J T Guy, and
W E Samlowski, and
J H Costanzi
January 1983,
Investigational new drugs,
S A Taylor, and
T Fleming, and
D D Von Hoff, and
J D McCracken, and
R M Bukowski, and
R W Talley, and
R B Natale, and
J T Guy, and
W E Samlowski, and
J H Costanzi
January 1994,
Investigational new drugs,
S A Taylor, and
T Fleming, and
D D Von Hoff, and
J D McCracken, and
R M Bukowski, and
R W Talley, and
R B Natale, and
J T Guy, and
W E Samlowski, and
J H Costanzi
November 1984,
Cancer treatment reports,
S A Taylor, and
T Fleming, and
D D Von Hoff, and
J D McCracken, and
R M Bukowski, and
R W Talley, and
R B Natale, and
J T Guy, and
W E Samlowski, and
J H Costanzi
August 1993,
American journal of clinical oncology,
S A Taylor, and
T Fleming, and
D D Von Hoff, and
J D McCracken, and
R M Bukowski, and
R W Talley, and
R B Natale, and
J T Guy, and
W E Samlowski, and
J H Costanzi
January 1994,
Cancer investigation,
